Larimar Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Larimar Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-60.7%
Buyback Yield
Total Shareholder Yield | -60.7% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Jan 03We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Dec 18Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Oct 07Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans
Aug 09Larimar Therapeutics: More Data Still Needed
Jul 15Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
May 31We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Larimar under pressure as FDA puts clinical hold on CTI-1601 program
May 26Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Dec 15Larimar completes dosing in Friedreich’s Ataxia, provides program update
Dec 08Larimar Therapeutics (LRMR) Investor Presentation - Slideshow
Nov 16Larimar Therapeutics reports Q3 results
Nov 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if LRMR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LRMR's dividend payments have been increasing.
Dividend Yield vs Market
Larimar Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (LRMR) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.5% |
Industry Average (Biotechs) | 2.5% |
Analyst forecast (LRMR) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate LRMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LRMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate LRMR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LRMR has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 08:18 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Larimar Therapeutics, Inc. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joel Beatty | Baird |
Samantha Lynn Semenkow | Citigroup Inc |
Samantha Lynn Semenkow | Citigroup Inc |